Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease

Xiao, Bin; Wang, Yu; Li, Wei; Baker, Megan; Guo, Jian; Corbet, Kelly; Tsalik, Ephraim L.; Li, Qi-Jing; Palmer, Scott M.; Woods, Christopher W.; Li, Zhiguo; Chao, Nelson J.; He, You–Wen

doi:10.1182/blood-2013-06-510586

Cited by 120 publications

(145 citation statements)

References 44 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…Given the involvement of the skin and immune system in GvHD, the role of miRNAs in the pathogenesis of GvHD has been hypothesized. Xiao et al (59) provided supporting evidence for this hypothesis, and demonstrated that the plasma levels of miR-423, miR-199a-3p, miR-93* and miR-377 were significantly upregulated in patients with acute GvHD. In another study, Atarod and Dickinson (6) used Ingenuity Pathway Analysis to further investigate the interactions between the GvHD signalling pathway and miRNAs.…”

Section: Graft-versus-host Diseasesmentioning

confidence: 75%

Role of the microRNA-29 family in fibrotic skin diseases

et al. 2017

View full text Add to dashboard Cite

Abstract. Fibrotic skin diseases are characterized by the accumulation of collagen. The hallmarks of fibrotic skin diseases are unbalanced fibroblast proliferation and differentiation, extracellular matrix production and transforming growth factor-β signalling. Numerous studies have investigated the possibility that microRNAs (miRNAs or miRs) are involved in the pathogenesis of certain fibrotic diseases, including skin, heart, lung and liver diseases. miRNAs are a class of small non-coding RNAs, which modify gene expression by binding to target messenger RNA (mRNA) and blocking the translation or inducing the degradation of target mRNA. The biological relevance of miRNAs has been investigated in physiological and pathological conditions, and there is increasing evidence that the miR-29 family is associated with fibrotic diseases. The aim of the present review is to provide an up-to-date summary of current knowledge on the latest developments associated with the miR-29 family and fibrotic skin diseases.

show abstract

Section: Graft-versus-host Diseasesmentioning

confidence: 75%

Role of the microRNA-29 family in fibrotic skin diseases

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Further investigations into pre-transplant risk assessment could also include other potential predictors such as mRNA and microRNA expression. 60 …”

Section: Discussionmentioning

confidence: 99%

Predicting survival using clinical risk scores and non-HLA immunogenetics

Balavarca

Pearce

Norden

et al. 2015

Bone Marrow Transplant

View full text Add to dashboard Cite

Previous studies of non-histocompatibility leukocyte antigen (HLA) gene single-nucleotide polymorphisms (SNPs) on subgroups of patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) revealed an association with transplant outcome. This study further evaluated the association of non-HLA polymorphisms with overall survival in a cohort of 762 HSCT patients using data on 26 polymorphisms in 16 non-HLA genes. When viewed in addition to an already established clinical risk score (EBMT-score), three polymorphisms: rs8177374 in the gene for MyD88-adapter-like (MAL; P = 0.026), rs9340799 in the oestrogen receptor gene (ESR; P = 0.003) and rs1800795 in interleukin-6 (IL-6; P = 0.007) were found to be associated with reduced overall survival, whereas the haplo-genotype (ACC/ACC) in IL-10 was protective (P = 0.02). The addition of these non-HLA polymorphisms in a Cox regression model alongside the EBMT-score improved discrimination between risk groups and increased the level of prediction compared with the EBMT-score alone (gain in prediction capability for EBMT-genetic-score 10.8%). Results also demonstrated how changes in clinical practice through time have altered the effects of non-HLA analysis. The study illustrates the significance of non-HLA genotyping prior to HSCT and the importance of further investigation into non-HLA gene polymorphisms in risk prediction. Bone Marrow Transplantation INTRODUCTIONHaematopoietic stem cell transplantation (HSCT) is the major curative therapy for disorders of the blood and immune system. However, the rate of survival in patients with HSCT has remained at 40-60% for the last two decades, owing to post-transplant complications including infection, GvHD and relapse.Five relevant clinical factors influencing transplantation success in patients with haematological disorders, including CML, ALL and AML, have been identified by the European Group for Blood and Marrow Transplantation (EBMT). These risk factors (EBMT-factors) are patient age, sibling donor/matched unrelated donor (MUD), patient-donor gender combination, stage of disease and time from diagnosis to transplant. A clinical risk score (EMBT-score) utilising the EBMT-factors was proposed in order to aid the prediction and prevention of post-transplant complications.

show abstract

“…A clinical trial to further establish the significance of miR-155 in aGVHD is currently ongoing (ClinicalTrials.gov Identifier: NCT01521039). In addition, a group of miRs (miR-423, miR-199-3p, miR-93*, and miR-377) [6], miR-100 [7], miR-34a [8], and miR-146a [9] has also been identified to play an important role in the process of aGVHD after allo-HSCT. Atarod et al identified eight miRs (miR-146a, miR-155, miR-515, miR-346, miR-143, miR-373, miR-310, and miR-29) which could target different molecules in the GVHD signaling pathway [10].…”

Section: Introductionmentioning

confidence: 98%

Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease

Wang

Zhao

et al. 2015

Ann Hematol

View full text Add to dashboard Cite

Acute graft-versus-host disease (aGVHD) is one of the major causes of morbidity and mortality in patients receiving allogeneic hematopoietic cell transplantation (allo-HSCT). MicroRNAs (miRs) were found to have the potential to be the new biomarkers of aGVHD. In this study, we collected samples from 98 patients who underwent allo-HSCT; 63 patients developed aGVHD, and 35 patients did not. Plasma samples were collected at three time points (before aGVHD, at the onset of aGVHD, and after aGVHD) from 52 patients, and the miR-586 expression level was detected by quantitative real-time PCR. We found that the plasma miR-586 level was decreased at the onset of grade I-II aGVHD (P = 0.074). In contrast, when infections were detected, plasma miR-586 level was increased. Moreover, we detected the miR-586 expression level in patients who had infections but did not have aGVHD, and we found that miR-586 was upregulated (P = 0.005). We also compared the plasma miR-586 level at day 7 after transplantation between aGVHD patients and control patients. In the aGVHD group, there was a considerably higher miR-586 expression in comparison with the non-aGVHD group (P < 0.05). A more significant difference between the two groups was found when the patients with infections were excluded (P = 0.004). Furthermore, receive operating characteristic (ROC) analysis indicated that a higher expression level of miR-586 at day 7 could predict impending aGVHD. The optimal cutoff value of miR-586 to predict aGVHD was 2200 copies/μL with a sensitivity of 87.5 % and specificity of 55.0 %, and the area under the curve (AUC) was 0.739 (95 % CI 0.598-0.880, P = 0.004). Our study suggests that miR-586 might participate in the occurrence of aGVHD and could be a putative target for novel aGVHD therapy. The plasma level of miR-586 at day 7 after allo-HSCT would be a potential biomarker for predicting the occurrence of aGVHD.

show abstract

Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease

Cited by 120 publications

References 44 publications

Role of the microRNA-29 family in fibrotic skin diseases

Role of the microRNA-29 family in fibrotic skin diseases

Predicting survival using clinical risk scores and non-HLA immunogenetics

Plasma microRNA-586 is a new biomarker for acute graft-versus-host disease

Contact Info

Product

Resources

About